MSD’s Therapy Area Community Grants Programme

Save Print

July 15, 2020 5:38 pm +00:00

News Release

EMBARGOED FOR RELEASE UNTIL WEDNESDAY, 15 JULY 2020, 12:00 GMT

Media Contacts:

Harry Brady

+44 (1992) 455433

Olivia Finucane

+44 7881 262476

MSD’s Therapy Area Community Grants Programme now open for applications

MSD launches therapy area community grants programme to support and enable patient-centred projects aimed at empowering patients and improving outcomes

HODDESDON, UK, 15th July, 2020 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today the launch of a new therapy area community grants programme, aimed at providing funding support for projects designed to inform and empower patients, and deliver improvements in patient outcomes and experience in the UK.

Open to all UK-based organisations that meet the criteria, the new initiative will fund a number of independent projects from organisations looking to support the needs of their respective populations or communities, specifically in the areas of HIV, HPV, cancer and antimicrobial resistance, where MSD has particular expertise.

Organisations which serve the patient community, such as patient advocacy and support groups, are often closest to the day-to-day needs of patients, and how they relate to the health system and treatment pathways. These organisations play a widespread and pivotal role in advancing and improving the healthcare outcomes and experience for patients in the UK.

“We are delighted to be able to offer this new programme of support to groups working in the fields of HIV, HPV, cancer and antimicrobial resistance” said David Peacock, Managing Director MSD UK & Ireland. “Our ultimate goal is to improve outcomes and save lives, and we hope that, by supporting the community in this way, together, we can help realise this ambition.”

Details of MSD’s new Therapy Area Community Grants Programme and eligibility criteria can be accessed via the MSD UK affiliate website: https://www.msduk.com/partnerships/partnerships.xhtml#grants. Organisations have until 14th August 2020 to submit their applications.

If you have any questions about any of the four schemes then please contact us at: Grantscommittee@msd.com. Please indicate in the subject line of your email which scheme you are enquiring about.

About MSD

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on TwitterInstagramLinkedInYouTube and Facebook.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

GB-NON-02956 | Date of Preparation: July 2020